Oncopeptides Q1 2025 - Strong Q/Q Growth with Japan the Next Catalyst
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Redeye via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
2025-05-21 11:02:00
Redey comments on Oncopeptides’ first quarter report 2025. The growth quarter on quarter was 34%, despite a 5% FX headwind. Discussions about a potential deal in Japan are still ongoing. We believe the sales growth trend is stabilising with growing uptake from new markets.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/